{
    "2020-12-05": [
        [
            {
                "time": "2023-10-05",
                "original_text": "AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "VENCLEXTA",
                        "VENCLYXTO",
                        "venetoclax",
                        "Chronic Lymphocytic Leukemia",
                        "Extended Follow-Up",
                        "Fixed Duration Treatment"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)",
                "features": {
                    "keywords": [
                        "IMBRUVICA",
                        "ibrutinib",
                        "VENCLEXTA",
                        "VENCLYXTO",
                        "venetoclax",
                        "Disease-Free Survival",
                        "Combination Therapy",
                        "Previously Untreated Patients",
                        "Chronic Lymphocytic Leukemia"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}